ConductScience.org, home

Library / Trial comparisons

Cangrelor Treatment Arm vs Clopidogrel Treatment Arm: The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.0470.04170.0529wilsonClinicalTrials.gov
Risk in group 20.05890.05290.0654wilsonClinicalTrials.gov
Risk difference, group 1 minus group 2-0.0119-0.0203-0.0035newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 20.7980.680.936logClinicalTrials.gov
Odds ratio, group 1 over group 20.7880.6660.933logClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on Cangrelor Treatment Arm than on Clopidogrel Treatment Arm84.149.2286from the risk difference intervalClinicalTrials.gov

Groups 2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Cangrelor Treatment Arm2575,470OG000ClinicalTrials.gov
Group 2Clopidogrel Treatment Arm3225,469OG001ClinicalTrials.gov

Outcome 5

FieldValueSource
TypePRIMARYClinicalTrials.gov
TitleThe Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)ClinicalTrials.gov
DescriptionClinical Events Committee (CEC)-adjudicated results (modified intent-to-treat \[mITT\] population)ClinicalTrials.gov
Time frame48 hours after randomizationClinicalTrials.gov
PopulationClinicalTrials.gov

Trial 8

FieldValueSource
TitleA Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)ClinicalTrials.gov
NCT numberNCT01156571ClinicalTrials.gov
PhasesPHASE3ClinicalTrials.gov
ConditionsAtherosclerosis, Percutaneous Coronary Intervention, Acute Coronary SyndromeClinicalTrials.gov
Interventionscangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelorClinicalTrials.gov
Lead sponsorThe Medicines CompanyClinicalTrials.gov
Results first posted2013-06-18ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT01156571?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.